280 related articles for article (PubMed ID: 17109346)
1. Reductions in cross-neutralizing antibody responses in infants after attenuation of the human rotavirus vaccine candidate 89-12.
Ward RL; Kirkwood CD; Sander DS; Smith VE; Shao M; Bean JA; Sack DA; Bernstein DI
J Infect Dis; 2006 Dec; 194(12):1729-36. PubMed ID: 17109346
[TBL] [Abstract][Full Text] [Related]
2. Porcine rotavirus strain Gottfried-based human rotavirus candidate vaccines: construction and characterization.
Hoshino Y; Jones RW; Ross J; Kapikian AZ
Vaccine; 2005 May; 23(29):3791-9. PubMed ID: 15893616
[TBL] [Abstract][Full Text] [Related]
3. Homotypic and heterotypic serum neutralizing antibody response to rotavirus proteins following natural primary infection and reinfection in children.
Gorrell RJ; Bishop RF
J Med Virol; 1999 Feb; 57(2):204-11. PubMed ID: 9892409
[TBL] [Abstract][Full Text] [Related]
4. Neonatal administration of rhesus rotavirus tetravalent vaccine.
Vesikari T; Karvonen A; Forrest BD; Hoshino Y; Chanock RM; Kapikian AZ
Pediatr Infect Dis J; 2006 Feb; 25(2):118-22. PubMed ID: 16462287
[TBL] [Abstract][Full Text] [Related]
5. Live attenuated human rotavirus vaccine, Rotarix.
Bernstein DI
Semin Pediatr Infect Dis; 2006 Oct; 17(4):188-94. PubMed ID: 17055369
[TBL] [Abstract][Full Text] [Related]
6. Concomitant use of the oral pentavalent human-bovine reassortant rotavirus vaccine and oral poliovirus vaccine.
Ciarlet M; Sani-Grosso R; Yuan G; Liu GF; Heaton PM; Gottesdiener KM; Arredondo JL; Schödel F
Pediatr Infect Dis J; 2008 Oct; 27(10):874-80. PubMed ID: 18756184
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of RIX4414, a live, attenuated rotavirus vaccine, in a randomized, double-blind, placebo-controlled phase 2 trial involving 2464 Singaporean infants.
Phua KB; Quak SH; Lee BW; Emmanuel SC; Goh P; Han HH; De Vos B; Bock HL
J Infect Dis; 2005 Sep; 192 Suppl 1():S6-S16. PubMed ID: 16088807
[TBL] [Abstract][Full Text] [Related]
8. Homotypic and heterotypic serum isotype-specific antibody responses to rotavirus nonstructural protein 4 and viral protein (VP) 4, VP6, and VP7 in infants who received selected live oral rotavirus vaccines.
Yuan L; Ishida S; Honma S; Patton JT; Hodgins DC; Kapikian AZ; Hoshino Y
J Infect Dis; 2004 May; 189(10):1833-45. PubMed ID: 15122520
[TBL] [Abstract][Full Text] [Related]
9. Influence of potential protective mechanisms on the development of live rotavirus vaccines.
Ward RL; Clark HF; Offit PA
J Infect Dis; 2010 Sep; 202 Suppl():S72-9. PubMed ID: 20684721
[TBL] [Abstract][Full Text] [Related]
10. Mucosal and systemic antibody responses and protection induced by a prime/boost rotavirus-DNA vaccine in a gnotobiotic pig model.
Yuan L; Azevedo MS; Gonzalez AM; Jeong KI; Van Nguyen T; Lewis P; Iosef C; Herrmann JE; Saif LJ
Vaccine; 2005 Jun; 23(30):3925-36. PubMed ID: 15917114
[TBL] [Abstract][Full Text] [Related]
11. Effects of the potency and composition of the multivalent human-bovine (WC3) reassortant rotavirus vaccine on efficacy, safety and immunogenicity in healthy infants.
Vesikari T; Clark HF; Offit PA; Dallas MJ; DiStefano DJ; Goveia MG; Ward RL; Schödel F; Karvonen A; Drummond JE; DiNubile MJ; Heaton PM
Vaccine; 2006 May; 24(22):4821-9. PubMed ID: 16621194
[TBL] [Abstract][Full Text] [Related]
12. Safety, efficacy, and immunogenicity of a live, quadrivalent human-bovine reassortant rotavirus vaccine in healthy infants.
Clark HF; Bernstein DI; Dennehy PH; Offit P; Pichichero M; Treanor J; Ward RL; Krah DL; Shaw A; Dallas MJ; Laura D; Eiden JJ; Ivanoff N; Kaplan KM; Heaton P
J Pediatr; 2004 Feb; 144(2):184-90. PubMed ID: 14760258
[TBL] [Abstract][Full Text] [Related]
13. Immunogenicity of the pentavalent rotavirus vaccine among infants in two developing countries in Asia, Bangladesh and Vietnam.
Shin S; Anh DD; Zaman K; Yunus M; Mai le TP; Thiem VD; Azim T; Victor JC; Dallas MJ; Steele AD; Neuzil KM; Ciarlet M
Vaccine; 2012 Apr; 30 Suppl 1():A106-13. PubMed ID: 22520119
[TBL] [Abstract][Full Text] [Related]
14. Systemic and intestinal antibody responses to NSP4 enterotoxin of Wa human rotavirus in a gnotobiotic pig model of human rotavirus disease.
Iosef C; Chang KO; Azevedo MS; Saif LJ
J Med Virol; 2002 Sep; 68(1):119-28. PubMed ID: 12210439
[TBL] [Abstract][Full Text] [Related]
15. Rotarix (RIX4414): an oral human rotavirus vaccine.
O'Ryan M
Expert Rev Vaccines; 2007 Feb; 6(1):11-9. PubMed ID: 17280473
[TBL] [Abstract][Full Text] [Related]
16. Divergence of VP7 genes of G1 rotaviruses isolated from infants vaccinated with reassortant rhesus rotaviruses.
Jin Q; Ward RL; Knowlton DR; Gabbay YB; Linhares AC; Rappaport R; Woods PA; Glass RI; Gentsch JR
Arch Virol; 1996; 141(11):2057-76. PubMed ID: 8973523
[TBL] [Abstract][Full Text] [Related]
17. The new pentavalent rotavirus vaccine composed of bovine (strain WC3) -human rotavirus reassortants.
Clark HF; Offit PA; Plotkin SA; Heaton PM
Pediatr Infect Dis J; 2006 Jul; 25(7):577-83. PubMed ID: 16804425
[TBL] [Abstract][Full Text] [Related]
18. Rotavirus immunoglobulin a responses stimulated by each of 3 doses of a quadrivalent human/bovine reassortant rotavirus vaccine.
Ward RL; Bernstein DI; Smith VE; Sander DS; Shaw A; Eiden JJ; Heaton P; Offit PA; Clark HF
J Infect Dis; 2004 Jun; 189(12):2290-3. PubMed ID: 15181577
[TBL] [Abstract][Full Text] [Related]
19. Efficacy, immunogenicity, and safety of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine at the end of shelf life.
Block SL; Vesikari T; Goveia MG; Rivers SB; Adeyi BA; Dallas MJ; Bauder J; Boslego JW; Heaton PM;
Pediatrics; 2007 Jan; 119(1):11-8. PubMed ID: 17200266
[TBL] [Abstract][Full Text] [Related]
20. Dose response and efficacy of a live, attenuated human rotavirus vaccine in Mexican infants.
Ruiz-Palacios GM; Guerrero ML; Bautista-Márquez A; Ortega-Gallegos H; Tuz-Dzib F; Reyes-González L; Rosales-Pedraza G; Martínez-López J; Castañón-Acosta E; Cervantes Y; Costa-Clemens S; DeVos B
Pediatrics; 2007 Aug; 120(2):e253-61. PubMed ID: 17606534
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
